Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

The main difference between going public through an initial public offering (IPO) and staying private lies in ownership ...

AirBaltic continues to work on plans for an initial public offering (IPO), which is now set to take place in the spring of ...

Spanish travel technology firm HBX Group is considering announcing plans for an initial public offering as early as next week ...

Maze Therapeutics has filed for an initial public offering with the Securities and Exchange Commission. The San Francisco-based human genetics biotech company didn't say Tuesday how many shares it ...

Quadrant Future Tek IPO receives overwhelming response, closes Thursday with price band of ₹275-290, funds for long-term ...

Chinese toy maker Bloks Group has raised $215 million in a Hong Kong initial public offering (IPO) by pricing its shares at the top of the indicated range, according to a term sheet reviewed by ...

A biopharmaceutical company and its executives misled investors ahead of its 2024 initial public offering about a key ...

Indobell Insulation’s IPO, worth ₹10.14 crore, was fully subscribed on its first day. The offering is priced at ₹46 per share ...

Drug developer Maze Therapeutics Inc.'s rollercoaster ride is leading to the Bay Area's first biotech IPO filing of 2025.

Investors expect to see a continued uptick in U.S. IPO activity in 2025, bolstered by a bullish equities market and ...

The healthcare company began trading publicly on Tuesday and rose 15 per cent on debut as it hovered around the SAR139.60 ...